Vial Guide

Are peptides safe?

It depends on which peptide, what’s actually in the vial and how it’s used. Here is what’s known, what isn’t, and what regulators have found.

The short answer

“Peptide” describes a molecule’s size, not its safety. Some peptides are approved drugs: their risks were measured in trials and are printed on the label, along with who shouldn’t take them. Most peptides sold online aren’t. Many have been tested in a few dozen people or none, and no regulator checks what’s in the vials.

So the answer turns on three things: what the molecule does in the body, what’s actually in the vial, and how it’s used.

How much is known

Of the 94 compounds on this site:

  • Approved drug50 approved drugs somewhere in the world
  • Human studies23 tested in people but not approved
  • Preclinical21 known only from cell and animal studies

Each compound page answers 17 side-effect questions, 1,598 answers in all. Where each answer comes from:

From a product labelFrom human studiesFrom user reportsA precaution, not measuredSeen only in animalsStudied in people, not reportedNo human safety data

533 answers come from product labels and 235 from human studies. For 253 (16%), there are no human safety data at all, so the side effect can’t be ruled in or out.

Least studied in people, with “No data” for most of the 17 questions: Adamax, Cartalax, Pinealon, HGH Fragment 176-191, MGF, AHK-Cu, Epithalon, Humanin, PEG-MGF, Dihexa, FOXO4-DRI, PE-22-28, KPV, MOTS-c, TB-500, 5-Amino-1MQ, Follistatin-344, SLU-PP-332 and CJC-1295 (no DAC).

Risks from what the molecule does

A pure, correctly dosed peptide still acts on the body. Its risks follow from its target, and they’re shared across a class.

  • GLP-1 drugs. Nausea, vomiting and diarrhea are the most common side effects. Labels warn of pancreatitis, gallbladder disease and kidney injury from dehydration, and most US labels in the class carry a boxed warning about thyroid C-cell tumors seen in rodents.
  • Growth hormone secretagogues and HGH. Growth hormone raises blood sugar and can cause fluid retention, joint pain and carpal tunnel syndrome.
  • IGF-1 and its analogs. They lower blood sugar the way insulin does; mecasermin’s label warns of it.
  • Melanocortins. They darken skin and moles and commonly cause nausea and flushing; bremelanotide briefly raises blood pressure.
  • Reproductive hormones. They change sex-hormone levels, and most labels rule out pregnancy.
  • Repair peptides. BPC-157 and thymosin beta-4 promote blood vessel growth in animals, which tumors also rely on. None has been tested in people with cancer.

Each class page lists what its members share, with sources.

Risks from what’s in the vial

Research peptides are sold without any regulator checking their identity, purity, dose or sterility. When products have been tested:

  • FDA’s reviewers found certificates of analysis for peptides such as BPC-157, MOTS-c, CJC-1295 (no DAC) and Semax that lacked tests for impurities, microbes or bacterial toxins (endotoxins); some listed purity alone.
  • Vials have held less than their label or a different molecule. Melanotan 2 vials labeled 10 mg held 4.3 to 8.8 mg; seized CJC-1295 (no DAC) and ipamorelin powders held glycine-extended variants; and vials sold as HGH Fragment 176-191 often list AOD9604’s sequence instead.
  • Of 44 products sold online as SARMs, only 23 contained one; 17 held other unapproved drugs, including MK-677, and 4 held no active drug at all.
  • In 2026, injections compounded from supplement-grade glutathione caused reactions to bacterial toxins, including low blood pressure and shock, in more than 25 people in at least 4 states. Victoria, Australia linked six cases of acute liver injury to unapproved products labeled retatrutide.
  • FDA is aware of counterfeit Ozempic in the US market, and has warned sellers of semaglutide, tirzepatide and retatrutide labeled “for research purposes.”

What a lab report should show

Risks from how it’s used

  • Dosing errors. Mixing up units, mL and mg has led people to inject 5 to 20 times the intended dose, FDA reports. See units and conversions.
  • Doubling up on one target. Two compounds that act the same way, such as two GLP-1 drugs, add up their effects. The stack check flags these overlaps.
  • Shared needles and vials. They can pass on hepatitis B, hepatitis C and HIV.
  • No monitoring. Approved drugs come with checks, such as blood sugar on tesamorelin and skin exams on afamelanotide (Scenesse). Research use usually has none.
  • Your situation. Pregnancy, breastfeeding, kidney or liver disease and surgery all change the answer, and most compounds have no data for them.

What regulators have said

FDA. Reviewing peptides nominated for compounding, FDA flagged injected peptides for possible immune reactions, peptide-related impurities and little or no human safety data. Most nominations were withdrawn in April 2026, which took those peptides out of FDA’s Category 2 without approving them; ipamorelin and kisspeptin-10 remain in it. In July 2026, FDA’s advisory committee voted to add BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon to the list pharmacies may compound from, though FDA’s own reviewers had argued against four of them, and voted against DSIP. FDA hasn’t acted on the votes.

“Research use only.” The label doesn’t mean anyone checked the product, and it isn’t a legal route to human use. In warning letters to online sellers in March 2026, FDA rejected the disclaimer where the sellers’ websites showed the products were meant for people.

Sport. WADA bans most growth-promoting peptides at all times, and any drug with no current human approval anywhere. Each compound’s page gives its listing; see legal status.

Before using any peptide

None of this replaces a licensed clinician, who can check what a website can’t: your health, your medicines and your bloodwork.

Sources: each compound’s page and class page, where every fact above is cited; FDA, bulk drug substances that may present significant safety risks (April 22, 2026); FDA Pharmacy Compounding Advisory Committee minutes (July 23–24, 2026); FDA warning letters to online peptide sellers (March 31, 2026); FDA, concerns with unapproved GLP-1 drugs used for weight loss; FDA alert on dosing errors with compounded semaglutide (July 2024); CDC, adverse events linked to injectable glutathione (September 2026); Victoria Department of Health alert on products labeled retatrutide (June 2026); Van Wagoner et al., JAMA 2017, PMID 29183075; Breindahl et al., Drug Test Anal 2015, PMID 24771717.

By Vial Guide editorsLast reviewed

How we review